{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:11:27Z","timestamp":1790431887087,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T00:00:00Z","timestamp":1524528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["128608\u2010RSGI\u201015\u2010211\u201001\u2010CPHPS"],"award-info":[{"award-number":["128608\u2010RSGI\u201015\u2010211\u201001\u2010CPHPS"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54GM115677"],"award-info":[{"award-number":["U54GM115677"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    In aggressive lymphomas, discrepancies in survival reported from experimental and observational studies may reflect selective non\u2010enrolment of high\u2010risk patients in trials. We examined the association between time from diagnosis to chemotherapy and overall survival in diffuse large B\u2010cell (\n                    <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>\n                    ), Burkitt (\n                    <jats:styled-content style=\"fixed-case\">BL<\/jats:styled-content>\n                    ), mantle cell (\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    ) and peripheral T\u2010cell lymphoma (\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    ), using National Cancer Data Base records of 130\u00a0549 patients treated in 2004\u20132014. Across the histologies, patients who started chemotherapy within 7\u00a0days of diagnosis had more often high International Prognostic Index (\n                    <jats:styled-content style=\"fixed-case\">IPI<\/jats:styled-content>\n                    ) or advanced\u2010stage disease. The discrepancy in 3\u2010year survival between groups treated within 7 or &gt;30\u00a0days from diagnosis ranged from 14% in\n                    <jats:styled-content style=\"fixed-case\">BL<\/jats:styled-content>\n                    to 30% in\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    . After adjusting for the\n                    <jats:styled-content style=\"fixed-case\">IPI<\/jats:styled-content>\n                    , time to treatment was significantly associated with shorter overall survival. Using the group treated &gt;30\u00a0days from diagnosis as reference, patients treated within 7\u00a0days had a hazard ratio of 1\u00b738 [95% confidence interval (\n                    <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                    ), 1\u00b728\u20131\u00b748] in\n                    <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>\n                    , 1\u00b742 (95%\n                    <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                    , 1\u00b722\u20131\u00b766) in\n                    <jats:styled-content style=\"fixed-case\">BL<\/jats:styled-content>\n                    , 2\u00b723 (95%\n                    <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                    , 1\u00b779\u20132\u00b778) in\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    and 1\u00b746 (95%\n                    <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                    , 1\u00b718\u20131\u00b781) in\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    . Time from diagnosis to treatment may reflect high\u2010risk features uncaptured by standard prognostic assessments. Clinical trials should accommodate patients who need urgent therapy to improve external validity and detect treatment effects in high\u2010risk groups.\n                  <\/jats:p>","DOI":"10.1111\/bjh.15224","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T05:26:26Z","timestamp":1524547586000},"page":"495-504","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Time to treatment is an independent prognostic factor in aggressive non\u2010Hodgkin lymphomas"],"prefix":"10.1111","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"first","affiliation":[{"name":"Department of Medicine Alpert Medical School of Brown University Providence RI USA"},{"name":"Division of Hematology and Oncology Rhode Island Hospital Providence RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ollila","sequence":"additional","affiliation":[{"name":"Department of Medicine Alpert Medical School of Brown University Providence RI USA"},{"name":"Division of Hematology and Oncology Rhode Island Hospital Providence RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-6863","authenticated-orcid":false,"given":"John L.","family":"Reagan","sequence":"additional","affiliation":[{"name":"Department of Medicine Alpert Medical School of Brown University Providence RI USA"},{"name":"Division of Hematology and Oncology Rhode Island Hospital Providence RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,24]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"AJCC Cancer Staging Manual","author":"Amin M.B.","year":"2016"},{"key":"e_1_2_9_3_1","article-title":"Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries","author":"Augustin A.","year":"2017","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3947"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6905"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28264"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23638"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087601"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30444-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647602"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08947.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2980"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308392"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016000927"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq359"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-538504"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7916"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793984"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2784"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.167742"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood.V128.22.3034.3034","article-title":"Time from diagnosis to initiation of treatment of DLBCL and implication for potential selection bias in clinical trials","volume":"128","author":"Maurer M.J.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw257"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0610-8"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01787.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13202"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3660"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1994.tb01754.x"},{"key":"e_1_2_9_35_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2017"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq214"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu109"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9842"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-524108"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T08:44:16Z","timestamp":1695458656000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,24]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/bjh.15224"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15224","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,24]]},"assertion":[{"value":"2018-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}